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Abstract
Aim: To identify existing comorbidity measures and summarise their association with acute 
coronary syndrome (ACS) outcomes.
Methods: We searched published studies from MEDLINE (OVIDSP) and EMBASE from 
inception to March 2021, studies of the pre-specified conference proceedings from Web of 
Science since May 2017, and studies included in any relevant systematic reviews. Studies that 
reported no comorbidity measures, no association of comorbid burden with ACS outcomes, or 
only used a comorbidity measure as a confounder without further information were excluded. 
After independent screening by three reviewers, data extraction and risk of bias assessment of 
each included study was undertaken. Results were narratively synthesised. 
Results: Of 4166 potentially eligible studies identified, 12 (combined n=6,885,982 participants) 
were included. Most studies had a high risk of bias at quality assessment. Six different types of 
comorbidity measures were identified with the Charlson comorbidity index (CCI) the most widely 
used measure among studies. Overall, the greater the comorbid burden or the higher comorbidity 
scores recorded, the greater was the association with the risk of mortality. 
Conclusion: The review summarised different comorbidity measures and reported that higher 
comorbidity scores were associated with worse ACS outcomes. The CCI is the most widely 
measure of comorbid burden and shows additive value to clinical risk scores in use. 
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Observational studies reporting associations between comorbidity measures and ACS outcomes 
were identified using bibliographical searches of Medline, EMBASE and Web of Science. All 
articles were screened for eligibility using the pre-defined inclusion criteria. Meta-analysis was not 
possible due to differences in the study designs and outcomes in different studies. 
Message for the clinic
CCI is the most widely used comorbidity measure to investigate the relationship between 
comorbid burden and outcomes in patients with ACS. While comorbidity burden according to all 
five measures was associated with worse outcomes in the context of ACS, our review of model 
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Introduction
Cardiovascular disease (CVD) remains the leading cause of death globally, representing 31% of 
all deaths. (1) Acute coronary syndromes (ACS) are a common acute presentation of CVD, and 
are associated with significant morbidity, mortality and economic burden to society. (2) As the 
world’s population is ageing rapidly, one consequence is the increase in the prevalence of chronic 
comorbid diseases, particularly in cardiovascular conditions such as in ACS. Comorbidity is the 
presence of more than one additional condition co-occurring with a primary condition. (3) It is 
well established that patients with a significant comorbidity burden are at increased risk of adverse 
outcomes and are challenging to treat. (4) Increasing comorbidity burden in patients with ACS is 
associated with an increased risk of mortality and future cardiovascular events. (5,6) 
Comorbidities rarely occur in isolation, with ACS patients often having multiple comorbidities (7) 
that increases the complexity of clinical decision-making in these patients. (8,9)
The Charlson Comorbidity Index (CCI) and the Elixhauser Comorbidity Score (ECS) are 
measures of global comorbid burden and have both been widely used to predict prognosis amongst 
different medical conditions. (10,11) The original CCI is a measure of co-morbidity burden and 
provides a means of quantifying the prognostic impact of 19 comorbid conditions on the basis of 
their number and individual impact by means of a score developed as a prognostic indicator for 
patients with a variety of medical conditions. (12-14) The ECS is another measure of comorbid 
burden and comprises 30 comorbidity measures used to derive a weighted comorbidity score (van 
Walraven Elixhauser comorbidity score) to assess global comorbid burden. (15,16)
Previous systematic reviews assessing the prognostic impact of comorbid burden have been 
restricted to CCI and reported a positive association between higher CCI scores and risk of 
mortality in patients with ACS. (17) However, several other studies have evaluated the prognostic 
value of other comorbidity measures in ACS patients (18,19) with some literature indicating that 
ECS and other comorbidity measures might outperform CCI scores in outcome prediction. (20,21) 
There is still no systematic review conducted to summarise the totality of this evidence. Hence, the 
purpose of this systematic review was to identify existing comorbidity measures or indices that 
were used in ACS patients and report their associations with ACS outcomes.
Methods
We registered the protocol used for this review in the international prospective register of 
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conducted according to the guidance of systematic review and meta-analysis for prognostic factor 
studies proposed by Riley et al. (22)  
2.1 Data sources and searches
The bibliographic databases (MEDLINE (OvidSP), EMBASE (OvidSP)) were searched to identify 
all potentially relevant published studies from inception to March 2021. Web of Science was 
searched to identify potentially relevant unpublished abstracts from the following three conference 
journals: American Heart Association (AHA), American College of Cardiology (ACC) and 
European Society of Cardiology (ESC) from 2017 onwards. Reference lists of all included studies 
were scrutinised, especially the primary studies included in the relevant systematic reviews 
identified from each database. Searches used broad terms and combinations of these terms that 
were related to the concept of three core terms: ACS, comorbidity and measure (Supplementary 
Table 1). Search strategies combined a series of keywords with the most inclusive suffix and 
database-specific Medical Subject Heading terms (MeSH) with appropriate Boolean operators 
(Supplementary Table 1). Our search strategies were further refined in consultation with an 
internal systematic review team prior to final execution. 
2.2 Study Selection
2.2.1 Inclusion criteria
The criteria for study selection mainly encompass the five domains: search designs, publication 
types, patient population, clinical outcomes and comorbidity measures. More detailed inclusion 
and exclusion criteria for the review are provided in Supplementary Table 2. 
Study designs
Our literature search included randomized control trials (RCTs) as well as observational (cohort 
and case-control) studies. No language restriction was imposed. Non-human articles and study 
design papers were excluded.
Population of interest/outcome of interest
Selected studies were limited to patients hospitalised for an ACS. ACS was defined as either acute 
myocardial infarction (MI) (ST-elevated myocardial infarction (STEMI) and non-ST elevated 
myocardial infarction (NSTEMI)) or Unstable angina (UA). Studies with patients presenting 
without acute MI (such as stable angina, coronary heart disease, elective percutaneous coronary 
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three with no restriction on time point of outcome measurement: 1) mortality, 2) major adverse 
cardiac and cerebrovascular events (MACCE), 3) bleeding.
Comorbidity measures as prognostic factors
Comorbid burden of patients was measured by composite comorbidity measures (scores or 
indexes). The comorbidity measures could be developed based on a simple count of comorbidities 
or on a numerical system with weightings assigned to individual comorbidities to produce a final 
weighted score. Studies must report at least one comorbidity measure (score or index) as primary 
prognostic factors used to predict the association of comorbid burden with ACS outcomes. It was 
agreed (decided by consensus of J.E., G.P. and M.A.M.) that studies only applying comorbidity 
measure as a confounder without estimate effects of outcomes were excluded.
2.2.2 Selection process
We used references management software (Rayyan) to screen the studies and record reviewer 
decisions. After removing duplicates, every abstract was screened independently by two reviewers 
(F.Z., C.W.) based on our inclusion and exclusion criteria defined above. Subsequently, any 
potentially relevant articles were obtained for full text review independently by three reviewers 
(F.Z., C.W. and Y.C.). The final study inclusion was decided by the senior authors (J.E., G.P. and 
M.A.M.)  
2.3 Data extraction and quality appraisal 
Data extraction was completed independently by two reviewers using a pre-formatted Excel 
spreadsheet according to the critical appraisal and data extraction for systematic reviews of 
prognostic factor studies (CHARMS-PF) checklist. (22,23) We contacted the authors of included 
studies where necessary data was missing or methodological information was not clear. 
Information collected from the studies include the authors, year of publication, country, study 
design, study population, patient characteristics, sample size, database used, outcomes, design of 
comorbidity measures, variables included in comorbidity measures, modelling method and how 
comorbidity measures were included in the model (continuous or categorical), association between 
comorbid burden and outcomes, prognostic effect estimates and their CIs, adjustment factors used, 
if validated or not, and summary of main findings.
Quality assessment of the studies was performed using the Quality In Prognostic factor Studies 
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and colleagues in 2013 for systematic reviews of prognostic factor studies by examining risk of 
bias (RoB) across the following six domains: study participation, study attrition, prognostic factor 
measurement, outcome measurement, adjustment for other prognostic factors, and statistical 
analysis and reporting. Each of the 6 domains includes several prompting items, which were taken 
together to obtain the judgement of risk of bias in each domain (high, moderate, or low risk of 
bias). The method used to determine the overall risk of bias for each study was described by 
Grooten et al. (25): a study having six low RoB or only having one moderate RoB was classified 
as low RoB (green); if more than one domain were assessed as high RoB, or ≥ 3 moderate RoB, 
then this article was treated as high RoB (red); the remaining papers in between were considered 
as moderate RoB (yellow). Three reviewers independently completed this assessment, and the 
final decisions were reviewed and made by the senior authors.
2.4 Data synthesis and analysis
A narrative synthesis was conducted instead of implementing a meta-analysis, due to the 
heterogeneity related to the length of follow-up, modelling used, how the comorbidity measure 
was modelled, adjustment variables used, and ACS presentation. Data were summarised across 
studies and interpreted by 1) describing the characteristics of the included studies, 2) determining 
the design of comorbidity measures used to define the comorbid burden and identifying how 
comorbidity measures were coded in the model, 3) synthesising the association between comorbid 
burden and ACS outcomes and the prognostic effect sizes.
Results
A total of 4166 studies were retrieved from our search. After excluding studies that did not meet 
the inclusion criteria, a total of four retrospective studies (26-29) and eight prospective studies 
(18,19,30-35) were included (Fig. 1). In addition, we identified another ten studies (20,21,36-43) 
that did not report any prognostic impact of comorbidity measure on ACS outcomes however 
offered information on model comparison in terms of predictive performance of different 
comorbidity measures. 
3.1 Characteristics of the included studies
The study designs and cohort characteristics of each included paper are presented in Table 1. 
Among four retrospective studies, one (26) had a follow up of 24 years, two had an 11-year 
follow-up, (27,28) one had a follow up of one year. (29) The remaining eight prospective studies 
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conducted between 1984 and 2008 and published between 2004 and 2019, four studies that were 
published in 2020 used relatively new data (year 2004-2016). The majority of the studies were 
conducted in European countries including five from Spain (19,31,32,34,35), one from Italy, (30) 
one from Denmark (26) and one from Switzerland (33), with the exception of one from Israel (18) 
and two from the United States. (27,28) Most studies were published as a full research manuscript 
although two were published as an abstract. (32,34) There was no age limitation in most studies 
except three studies (26-28) with an age limit of 15 years old or higher and two studies (19,34) 
which focused on patients aged ≥65 years and aged ≥80 years, respectively.
Our review included a total of 6,885,982 patients with the sample size of individual studies 
ranging from 520 to 6,613,623 patients. The study populations comprised patients with ACS 
(N=6,645,339 in five study (27-29,33,34)), those with AMI (total N= 237,251 in three studies 
(18,26,31)), those with NSTEMI (total N=2652 in three studies (19,32,35)), and those with 
STEMI (N=740 in one study (30)). The mean ages ranged from 66 to 74 years old from studies 
which reported such data. The percentages of female patients varied between 27% and 42%. 
3.2 Quality Assessment of the Included Studies
Risk of bias (RoB) assessment based on the QUIPS tool showed that seven studies (18,19,30-
32,34,35) were at high RoB (see Fig. 2) mainly due to lack of information on “study attrition, 
prognostic factor measurement, statistical analysis and reporting” domains (e.g., no information on 
response rate for study participants, (35) no description of patients who dropped out, (30) 
methodological issues, (32) or selective reporting of results. (30,34) Two studies from 
Radovanovic et al. (33) and Hautamaki et al. (29) were moderate RoB. Only three studies left (26-
28) were evaluated as low RoB. Seven studies were at low RoB in the “outcome measurement” 
domain, whilst more than two-third of studies were at low RoB in “study participation and study 
confounding” domains.
3.3 Characteristics of comorbidity measures
The details of the comorbidity measures’ design, reported outcomes, modelling used and the 
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3.3.1 Comorbidity measures’ design
A total of six different types of comorbidity measures were identified in the studies examined: 1) 
Charlson comorbidity index (CCI), 2) Soroka Acute Myocardial Infarction (SAMI), 3) Simplified 
comorbidity measure (SCM), 4) Chronic comorbidity score (CS), 5) Simple comorbidity index 
(SCI), 6) Elixhauser comorbidity score (ECS). These comorbidity measures are summarised in 
Supplementary Table 3.
The CCI was the most widely used measure in this review with seven studies (26,27,29,31-34) 
using CCI to define comorbid burden, with three (26,29,33) presenting use of the original CCI 
score (12) rather than Deyo modification (13). Four of these studies (26,27,31,33) computed CCI 
scores for each patient and categorised the scores into four levels of comorbidity (CCI=0, 1, 2 or 
≥3), one study categorised CCI scores into quartiles (34), whereas the studies by Ramirez-Marrero 
(32) and Hautamaki (29) applied CCI scores as a continuous variable. Only one study (28) used 
the ECS method and categorised ECS scores into five groups (ECS<0, 0, 1-5, 6-13, ≥14) and 
stratified the number of Elixhauser comorbidities into five groups (0, 1, 2, 3, 4, ≥5). One study 
(18) developed the SAMI risk score which consisted of 11 parameters. The total score for each 
patient was calculated to define comorbid burden and used as a continuous variable in the model. 
The SCM was used as a categorical variable with three levels (SCM=0-1, 2, ≥3) to define the 
comorbid burden according to the number of the six comorbidities. (19) A summary CS was 
computed for each patient by summing disease-specific scores and then divided into a categorical 
variable with three levels (from CS-1 to CS-3) with increasing comorbid burden (30). One study 
(35) stratified patients by summing the total SCI scores into three groups: SCI=0, 1-2, ≥3. 
3.3.2 Reported outcomes and modelling used
The clinical outcomes reported among the 12 studies varied, with the most frequently reported was 
mortality at various follow-up periods. One-year all-cause mortality was reported in six studies, 
(18,19,30,31,33,35) whilst in-hospital mortality was reported in four studies. (27,28,32,33) Other 
less frequent outcomes in individual studies included: 30-day mortality, (26,29,31) 6-month 
mortality, (29,34) 2-year mortality, (29,32) and in-hospital MACCE (27,28). The modelling 
approaches used to assess the association of comorbidity measures with clinical outcomes were 
cox proportional hazard regression identified in seven studies (19,26,29-31,34,35) and logistic 
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3.3.3 Synthesising the association of comorbidity measures with reported outcomes
Overall, the associations reported (ORs and HRs, in Table 2) between comorbidity measures and 
clinical outcomes indicated patients in a higher comorbid group or with higher scores were 
associated with a higher risk of adverse events. For example, five studies that treated comorbid 
burden as categorical and reported long-term mortality (≥ one-year), indicated the adjusted HRs of 
the highest comorbid group (vs the reference group) ranged from 1.9 to 4.8 (95% CIs located 
between 1.2 and 8.5); (19,26,30,31,35) for 30-day mortality, two studies suggested the adjusted 
HRs of the highest comorbid group ranged from about 1.6 to 2 (95% CIs from 0.8 to 2.8); (26,35) 
two studies (29,34) that used CCI as continuous scores to predict over 6-month mortality also 
reported the adjusted HRs of per one-unit increase score ranging from 1.15 to 1.25 (95% CIs from 
1.06 to 1.33). In studies using logistic regression models with long-term mortality, two studies that 
treated comorbidity scores as continuous variables reported ORs between 1.39 and 1.44 (95% CIs 
from 1.3 to 1.53) per one-unit increase in score. (18,33) For in-hospital mortality, two studies 
(27,32) that used CCI scores as continuous variable reported that higher comorbid burden was 
associated with a greater mortality risk (OR 1.6, 95%CI, 1.4-1.8 and OR 1.13, 95%CI, 1.12-1.14), 
whilst one study (33) that used CCI scores as categorical variable reported that the highest 
comorbid group had an adjusted OR of 2.2 (95%CI 1.86-2.57) for in-hospital mortality compared 
to the reference group. The study (28) which used ECS scores to define comorbid burden reported 
the highest burden group had a 4.8-fold increase in the odds of in-hospital mortality compared to 
the lowest comorbid group (OR 4.81, 95%CI, 4.60-5.02). In addition to other outcomes, one study 
(32) reported the associations of MACE (OR 1.1, 95%CI, 1-1.2) and readmission for heart failure 
(OR 1.2, 95%CI, 1.04-1.3) with CCI scores used as continuous variables. Two studies (27,28) 
reported that continuous CCI scores and ECS scores were independently associated with increased 
odds of  in-hospital MACCE, major bleeding and acute ischemic stroke (MACCE: OR1.13, 
95%CI,1.12-1.14; OR1.08, 95%CI,1.07-1.13). Most studies reported adjusted estimates of the 
association between CCI score and outcomes while only two studies reported unadjusted estimates 
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3.4 Studies that only reported model comparison
We identified ten studies which only reported model comparisons using different comorbidity 
measures. Although these studies did not have information on prognosis as per our protocol, their 
findings on model comparison are relevant to our review.                                                                                                                                                                                       
Nine studies were published between 1994 and 2014 and one study was in 2020. A retrospective 
study design was present in eight studies (21,36-40,42,43) while a prospective design was 
identified in one study (20) and a historical inception cohort design was used in the remaining 
study. (41) The study population comprised mainly patients with AMI (N=419,009 in nine studies) 
and participants with ACS (N=1202 in one study), while the sample size ranged in the individual 
studies between 1202 and 162,299. Eight comorbidity measures were used in the studies 
(Supplementary Table 4). With different comorbidity measures as prognostic factors, the 
performances of logistic regressions (nine studies) and cox regression (one study) were assessed 
and compared. Of eight measures, the most common measures were CCI (nine studies) and ECS 
(six studies), which were also frequently compared and indicated that ECS outperforms CCI in 
these studies due to its higher model discrimination. In-hospital mortality was the main outcome in 
most studies. All the studies employed C-statistic as the method to assess and compare model 
performance. Five studies considered one or two additional methods including calibration slope, 
Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Nagelkerke R-square, 
and G-square statistic.
Discussion
4.1 Summary of included studies 
The aim of the present review was to provide an overview of existing measures used to evaluate 
comorbid burden in patients with ACS and investigate the prognostic impact of different measures 
of comorbid burden on ACS outcomes. We report that the most widely studied comorbidity 
measure used to investigate the relationship between comorbid burden and outcomes in patients 
with ACS is CCI. We found that a greater comorbidity burden irrespective of how it was measured 
/ defined was consistently associated with an increased risk of a variety of ACS outcomes 
including mortality and MACCE. Finally, our review also observed model comparisons using 
different comorbidity measures which implied ECS might have better performance than CCI.
Our review is the first analysis to study the prognostic impact of a broad range of comorbidity 
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representing data derived from over 6.5 million patients from diverse healthcare systems with a 
broad range of comorbidity measures used. Many of the identified comorbidity measures except 
the CS (30) have been externally validated, for example the CCI and the ECS were described in 
general medical populations and have been validated extensively in a number of medical 
conditions; (10-13,15,44) Nonetheless there were drawbacks to these studies. Several studies had 
selective reporting of results, thereby increasing the difficulty of quality assessment as important 
information was either omitted or unclear (e.g., missing data, adjustment variables). (24) 
Meanwhile, many of the comorbidity scores were created early using historical datasets with small 
simple sizes, where the prognostic impact of a particular comorbidity may have been only relevant 
to the population studied. As patterns of medical diagnosis and treatments evolve, the estimated 
magnitude and direction of association between comorbidity and adverse outcomes may change. 
For example, AIDS is scored as +6 points in the CCI score consistent with the poor outcomes of 
AIDS when the CCI score was developed, even though the longer-term outcomes of patients with 
AIDS have substantially improved in contemporary clinical practice. (45) In addition, most 
identified measures apart from CCI and ECS have been merely validated in specific populations 
and may not be suitable for assessment of prognosis in other groups of patients more widely. 
Finally, our review showed ECS was not used widely to investigate the association of comorbidity 
burden with ACS outcomes except one study published in 2019 (28), even though comparative 
studies suggest that it may be superior in predicting mortality in cardiovascular cohorts. 
(20,21,36,38)Previously a meta-analysis (17) has summarized the impact of CCI scores on 
cardiovascular diseases, which showed that a higher CCI score was associated with an increased 
risk of mortality in ACS patients, with each unit increase of CCI score associated with a 33% 
increased risk of mortality (RR 1.33, 95% CI 1.15-1.54). While this review quantifies the 
association of CCI scores with ACS outcomes in a larger number of studies, our analysis provides 
more granular insights into the impact of other comorbidity measures on ACS-related outcomes 
and highlighted that regardless of how it was defined, a higher comorbidity burden was associated 
with an increased risk of mortality or MACE. For example, NSTEACS patients with the highest 
comorbid burden (SCI ≥ 3) had an adjusted HR of 4.8 (95%CI: 2.7-8.5) for one-year mortality 
compared to those with no comorbidities (SCI=0). (35) Another study using CCI score as a 
continuous variable also showed NSTEACS patients with a higher comorbidity burden (CCI>0) 
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There are several reasons why ACS patients with greater comorbidity burden have an increased 
risk of adverse outcomes. A study (33) found that the higher the comorbid burden, the longer the 
delay between the symptom onset and admission. Besides, the symptoms were less typical and 
there was higher degree of haemodynamic instability which translated into higher Killip class. The 
6-month mortality of ACS patients with Killip class I vs class III/IV is around 4-5% vs 23-28%. 
(46,47) An important therapeutic goal in AMI is rapid coronary reperfusion and current guidelines 
recommend early routine invasive management particularly for STEMI (in the form of primary 
PCI) and high-risk NSTEMI presentations. (30) However, as highlighted by Sachis et al, invasive 
strategies are underused in comorbid patients in the context of ACS. (19) The most consistent 
finding across the studies identified in our review was the lower rate of utilization of coronary 
reperfusion therapy (e.g. PCI or thrombolysis) among ACS patients with higher comorbidity. 
(18,27,28,30,33,35) For example, Balzi et al (30) found that the proportion of patients receiving 
coronary reperfusion therapy reduced as the comorbidity increased, from 78.8% in the group with 
the least comorbidity to 41.9% in the group with the most comorbidities; two identified studies 
also reported that patients in higher CCI and ECS groups were less likely to receive coronary 
angiography or PCI (27,28). This phenomenon may be attributed to the perception that patients 
with high comorbidities do not benefit from invasive management or are poor candidates for 
revascularization. (35) Furthermore, there is evidence that comorbid patients undergoing coronary 
revascularisation with PCI are at greater risk from sustaining major bleeding complications and 
adverse outcomes. (7,44,48)
However, data does not support such a conservative approach to such patients, for example, a 
prospective study of 1017 NSTEACS patients hospitalized in Spain between 2006 and 2009 (35) 
demonstrated that coronary reperfusion was associated with a better prognosis than conservative 
therapy and the differences were more marked with increasing comorbid scores. Furthermore, in 
the sensitivity analysis conducted by Sanchis et al (19), in-hospital revascularization reduced 
mortality in both groups of patients with less than three comorbidities and patients with three or 
more comorbidities. Interestingly, the magnitude of mortality reduction was greater among more 
comorbid patients (20.3% vs 10.0%). 
A previous cohort study (49) has shown that the inclusion of measures of comorbidity burden to 
commonly used prognosis scores may improve their performance. The GRACE risk prediction 
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patients. (50) A study of 1202 ACS patients (42) reported that the prediction of outpatient 
mortality or cardiac-related events after discharge was improved when CCI scores were added to 
models using GRPI. Another study of 29,620 ACS patients from Switzerland from 2003 to 2012 
found that an increased comorbidity score (CCI>0) was an independent predictor of mortality 
despite adjustment for type of ACS and the therapy received. (33)
4.2 Summary of comparison studies
Among the model comparison studies, studies (20,21,36,38) report that ECS might perform better 
than the more widely used measure, CCI in prediction models for ACS-related outcomes. For 
example, a retrospective study of 144,687AMI patients using administrative data from five 
countries in 2008-2009 reported that ECS may achieve better discrimination than CCI in the 
prediction of 30-day mortality; (20) another two retrospective studies (21,38) with a totally of 
50,479 AMI patients from 1994 to 2001 in California and Canada demonstrated the same 
conclusion in predicting in-hospital mortality. A study with 8,961 AMI patients in 2001-2002 
demonstrated the ECS model had the largest C-statistic (best-discriminated ability) in predicting 
one-year follow-up mortality. (36) It is noted that, except for one study which was published 
recently in 2020, (43) four studies that included ECS applied it as separate binary variables in the 
model rather than using its scoring system due to lack of the weighting algorithm of the original 
ECS. Meanwhile, those studies also used CCI comorbidities as individual categorical variables 
instead of its weights that were more commonly used in practice. It is possible this way could 
cause ECS to have better predictive performance than CCI as ECS contained more conditions than 
CCI. Whilst ECS may have better discrimination than CCI, it is more complex to calculate than 
CCI, and so use of such comorbidity scores in clinical practice is often a balance between usability 
and performance.
4.3 Potential research interest
Although comparison studies in our review indicated that the Elixhauser method has more 
discriminative ability for the prediction of outcomes following ACS than the Charlson/ Deyo 
method, most studies used the CCI method to investigate the prognostic impact of comorbidity 
burden on ACS patients. The ECS method was rarely utilised except in one study published in 
2019. Future work is required to study the performance of the ECS in wider ACS populations 
using routinely collected administrative data in the future. Finally, although all included studies 
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is unclear whether the ACS patients classified into the comorbid groups using one measure are 
similarly classified using another comorbidity method. Therefore, it is essential to investigate how 
the agreement between these comorbidity methods is when classifying patients.
4.4 Limitations
Our analysis was performed complying with updated guidance (22) of the systemic review for 
prognostic factor studies. However, we also acknowledge limitations of our review. It only has a 
small number of studies included, with most of them were considered to be at high RoB based on 
the assessment of QUIPS. Owing to the heterogeneity of these studies, with substantial differences 
in modelling approaches, ACS outcomes and coding of comorbidity variables, a quantitative 
synthesis was not performed.
Conclusion
This systematic review paper identified six comorbidity measures, summarised their associations 
with ACS outcomes and assessed the quality of those studies.  We observed that CCI was the most 
widely used measure of comorbidity burden that was used to explore the relationship between 
comorbidity burden and ACS outcomes. Despite methodological heterogeneity among the 
identified studies, the review confirmed that irrespective of how comorbidity burden was defined, 
higher comorbidity burden or scores were associated with a greater risk of mortality and MACE in 
patients presenting with ACS. The addition of measures of comorbidity burden may help to 
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Table 1: Study design and characteristics of the included studies. 
 
Study ID Study design; Year; Country 
Study population 
size; type of 
population 
Age (median, 
mean ± SD, %) 
Female 
(%) 
Description of inclusion for participants 
Schmidt 
2012 
Retrospective cohort study; 
1984-2008; Denmark 
234,331 AMI 
Women: median 74 
in 1984 to median 
77 in 2008; 
Men: median 68 
37.9% 
All first-time hospitalizations for MI among 
Danish-born inhabitants aged 15 years or 
older. 
Plakht 2010 







No age limitation. 
 
Patients who had been admitted with AMI 
and discharged alive from hospital. 
Sanchis 2019 
Prospective cohort study; 
2002-2008 and 2010-2012; 
Spain 
920 NSTEACS 76.4 ± 7.0 42% 
Elderly (≥65) patients admitted for 
NSTEACS. 
Balzi 2005 
Prospective cohort study; 
2000-2001; Italy 
740 STEMI 69.5 ± 12.2 30.1% 
No age limitation. 
 
All residents in the Florence area arriving 
alive to the emergency department of 1 of 
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Sanchis 2011 
Prospective cohort study; 
2002-2008, Spain 
1017 NSTEACS 68 ± 13 
 
34% 
No age limitation. 
 
The patients who admitted to the Hospital 
with NSTEACS. 
Núñez 2004 
Prospective cohort study; 
2000-2003; Spain 
1035 AMI (508 
STEMI, 527 
NSTEMI) 
68 ± 3 32.1% 
No age limitation. 
 
Patients diagnosed with AMI who were 
admitted to hospital. 
Ramirez-
Marrero 2011 
Prospective cohort study; 
2004-2005; Spain 
715 NSTEACS 66.2 ± 11.2 NA 
No age limitation. 
 
Patients admitted to hospital for NSTEACS. 
Radovanovic 
2014 
Prospective cohort study; 
2002-2012; Swiss 
29,620 ACS 66.3 ± 12.8 27% 
No age limitation 
 
All ACS patients. ACS included acute MI 
and unstable angina. 
Zhang 2020a 
Retrospective cross-sectional 
study; 2004-2014; United 
State 
6,613,623 ACS  67 (56-79)  40.0% 
All adults (≥18 years) with the principal 











This article is protected by copyright. All rights reserved 
 
AMI: acute myocardial infarction; MI: myocardial infarction; NSTEACS: non-ST-segment elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; NA: not available; NSTEMI: 
non-ST-elevation myocardial infarction; ACS: acute coronary syndrome.  
Zhang 2020b 
Retrospective cross-sectional 
study; 2004-2014; US 
6,613,623 ACS  67 (56-79)  40.0% 
All adults (≥18 years) with the principal 
diagnosis of ACS. 
Pastor 2019 
Prospective cohort study; no 
study period found; Spain 
520 ACS   84.4 ± 3.6 38.5% 
Elderly (≥80 years) patients hospitalised 
after  NSTEACS. 
Hautamäki 
2020 
Retrospect cohort study; 
2015-2016; Finland 
1576 ACS 69.3 ± 11.8 30.9% 
Patients who underwent invasive 
evaluation by coronary angiography for a 
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Table 2: Summary of measured outcome, comorbid measures used, modelling used, association presented and effect characteristics.  
Study ID Outcomes 
Comorbidity 
measure used 
prognostic factor/covariate; type 
of variable 
Modelling 
Final prognostic effect estimates for 
comorbidity measure (unadjusted and 








The original CCI  
(19 conditions) 
CCI as prognostic factor. 
Summary scores as a categorical 
variable (0, 1, 2, ≥3) 
Cox proportional 
hazard regression 
30-day mortality:  
Results from unadjusted models: 
1 vs 0: HR=1.85 (95%CI: 1.73-1.98) 
2 vs 0: HR=2.09 (95%CI: 1.94-2.25) 
≥3 vs 0: HR=2.72 (95%CI: 2.53-2.91) 
 
Results from adjusted models: 
1 vs 0: HR=1.35 (95%CI: 1.26-1.45) 
2 vs 0: HR=1.52 (95%CI: 1.41-1.64) 
≥3 vs 0: HR=1.96 (95%CI: 1.83-2.11) 
 
31-365-day mortality:  
Results from unadjusted models: 
1 vs 0: HR=2.64 (95%CI: 2.42-2.87) 
2 vs 0: HR=3.61 (95%CI: 3.30-3.96) 
≥3 vs 0: HR=5.80 (95%CI: 5.34-6.31) 
 
Results from adjusted models: 
1 vs 0: HR=1.83 (95%CI: 1.68-2.00) 
2 vs 0: HR=2.50 (95%CI: 2.29-2.74) 
















SAMI as prognostic factor. 




Results from adjusted models: 







SCM as prognostic factor. 
Summary numbers of comorbidities 
as a categorical variable (0-1, 2, ≥3) 
Cox proportional 
hazard regression 
No results from unadjusted models. 
 
Results from adjusted models:  
2 vs 0-1: HR=1.29 (95%CI: 0.81-2.04)  








CS as a covariate. 
Summary scores and tertile to 3 
categories (cut-off values can vary) 
Cox proportional 
hazard regression 
No results from unadjusted models. 
 
Results from adjusted models:   
2 vs 1: HR=1.87 (95%CI: 1.04-3.38) 







SCI as prognostic factor. 
Summary points as a categorical 
variable (0, 1-2, ≥3) 
Cox proportional 
hazard regression 
No results from unadjusted models. 
 
Results from adjusted models:   
1-2 vs 0: HR=1.7 (95%CI: 1.0-3.1) 























CCI as prognostic factor. 
Summary scores as a categorical 




30-day mortality or reinfarction:  
No results from unadjusted models. 
 
Results from adjusted models: 
1 vs 0: HR=1.69 (95%CI: 1.10-2.59) 
2 vs 0: HR=1.78 (95%CI: 1.08-2.92) 
≥3 vs 0: HR=1.57 (95%CI: 0.87-2.83) 
 
1-year mortality or reinfarction: 
No results from unadjusted models. 
 
Results from adjusted models: 
1 vs 0: HR=1.62 (95%CI: 1.18-2.23) 
2 vs 0: HR=2.00 (95%CI: 1.39-2.89) 















CCI as prognostic factor. 
Summary scores as a continuous 
variable 
NA 
Unclear whether the results are from 
unadjusted or adjusted models: 
Intrahospital- phase mortality: 
OR=1.6 (95%CI: 1.4-1.8) 
Long-term (24-month) mortality: 
OR=1.3 (95%CI: 1.2-1.5) 
readmission for HF: 
OR=1.2 (95%CI: 1.04-1.3) 
MACESs during follow-up: 


















The original CCI 
(19 conditions) 
CCI as prognostic factor. 
 
For in-hospital mortality: 
Summary scores as a categorical 
variable, 
 
For 1-year mortality: 
Summary scores as a continuous 
variable 
Logistic regression 
In-hospital mortality:  
No results from unadjusted models. 
 
Results from adjusted models: 
1 vs 0: OR=1.36 (95%CI: 1.16-1.60) 
2 vs 0: OR=1.65 (95%CI: 1.38-1.97) 
≥3 vs 0: OR=2.20 (95%CI: 1.86-2.57) 
 
1-year mortality:  
No results from unadjusted models. 
 
Results from adjusted models: 
























CCI as prognostic factor; 
Summary scores as a categorical 
variable (0, 1, 2, ≥3); 
 
In sensitivity analysis, summary 
scores as a continuous variable. 
Logistic regression 
No results from unadjusted models. 
 
In-hospital mortality:  
Results from adjusted models: 
1 vs 0: OR=1.31 (95%CI: 1.29-1.34) 
2 vs 0: OR=1.45 (95%CI: 1.41-1.50) 
≥3 vs 0: OR=1.74 (95%CI: 1.68-1.79) 
 
OR=1.13 (95%CI: 1.12-1.14) 
 
In-hospital MACCE:  
Results from adjusted models: 
 1 vs 0: OR=1.23 (95%CI: 1.20-1.25) 
2 vs 0: OR=1.35 (95%CI: 1.32-1.38) 
≥3 vs 0: OR=1.70 (95%CI: 1.66-1.75) 
OR=1.13 (95%CI: 1.12-1.14) 
 
In-hospital Major bleeding:  
Results from adjusted models: 
1 vs 0: OR=1.16 (95%CI: 1.13-1.18) 
2 vs 0: OR=1.33 (95%CI: 1.29-1.37) 
≥3 vs 0: OR=1.64 (95%CI: 1.59-1.69) 
 
OR=1.12 (95%CI: 1.12-1.13) 
 
In-hospital Acute ischemic stroke:  
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1 vs 0: OR=1.26 (95%CI: 1.21-1.31) 
2 vs 0: OR=1.48 (95%CI: 1.41-1.55) 
≥3 vs 0: OR=2.35 (95%CI: 2.23-2.46) 
 
OR=1.18 (95%CI: 1.17-1.19) 
 
OR of Individual comorbidities for each 












ECS as prognostic factor; 
Summary scores as a categorical 
variable (<0, 0, 1-5, 6-13, ≥14); 
Summary number of comorbidity 
conditions as a categorical variable 
(0, 1, 2, 3, 4, ≥5); 
 
In sensitivity analysis, summary 
scores and number of comorbidity 
conditions as a continuous variable; 
 
Logistic regression 
No results from unadjusted models. 
 
In-hospital mortality: 
Results from adjusted models: 
0 vs <0: OR=1.25 (95%CI: 1.20-1.30) 
1-5 vs <0: OR=2.16 (95%CI: 2.09-2.24) 
6-13 vs <0: OR=3.30 (95%CI: 3.18-3.41) 
≥14 vs <0: OR=4.81 (95%CI: 4.60-5.02) 
 
1 vs 0: OR=0.95 (95%CI: 0.92-0.98) 
2 vs 0: OR=1.06 (95%CI: 1.02-1.09) 
3 vs 0: OR=1.19 (95%CI: 1.14-1.24) 
4 vs 0: OR=1.36 (95%CI: 1.30-1.41) 
≥5 vs 0: OR=1.65 (95%CI: 1.58-1.72) 
 
ECS:  OR=1.08 (95%CI: 1.07-1.09) 
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In-hospital MACCE:  
Results from adjusted models: 
0 vs <0: OR=1.11 (95%CI: 1.08-1.14) 
1-5 vs <0: OR=1.79 (95%CI: 1.75-1.84) 
6-13 vs <0: OR=2.86 (95%CI: 2.78-2.94) 
≥14 vs <0: OR=4.65 (95%CI: 4.49-4.82) 
 
1 vs 0: OR=0.98 (95%CI: 0.95-1.00) 
2 vs 0: OR=1.08 (95%CI: 1.04-1.11) 
3 vs 0: OR=1.22 (95%CI: 1.18-1.26) 
4 vs 0: OR=1.37 (95%CI: 1.32-1.43) 
≥5 vs 0: OR=1.69 (95%CI: 1.63-1.76) 
 
ECS:  OR=1.08 (95%CI: 1.07-1.09) 
NEC:  OR=1.12 (95%CI: 1.11-1.13) 
 
In-hospital Major bleeding: 
Results from adjusted models: 
0 vs <0: OR=0.61 (95%CI: 0.59-0.63) 
1-5 vs <0: OR=1.10 (95%CI: 1.07-1.14) 
6-13 vs <0: OR=1.49 (95%CI: 1.45-1.54) 
≥14 vs <0: OR=2.34 (95%CI: 2.25-2.45) 
 
1 vs 0: OR=1.12 (95%CI: 1.07-1.16) 
2 vs 0: OR=1.31 (95%CI: 1.26-1.36) 
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4 vs 0: OR=1.93 (95%CI: 1.84-2.04) 
≥5 vs 0: OR=2.59 (95%CI: 2.46-2.72) 
 
ECS:  OR=1.06 (95%CI: 1.05-1.07) 
NEC:  OR=1.19 (95%CI: 1.18-1.20) 
 
In-hospital Acute ischemic stroke:  
Results from adjusted models: 
0 vs <0: OR=0.98 (95%CI: 0.92-1.03) 
1-5 vs <0: OR=1.50 (95%CI: 1.41-1.58) 
6-13 vs <0: OR=3.03 (95%CI: 2.85-3.21) 
≥14 vs <0: OR=6.00 (95%CI: 5.61-6.42) 
 
1 vs 0: OR=1.28 (95%CI: 1.18-1.38) 
2 vs 0: OR=1.64 (95%CI: 1.52-1.77) 
3 vs 0: OR=2.00 (95%CI: 1.84-2.16) 
4 vs 0: OR=2.31 (95%CI: 2.13-2.51) 
≥5 vs 0: OR=2.98 (95%CI: 2.73-3.24) 
 
ECS:  OR=1.10 (95%CI: 1.09-1.11) 
NEC:  OR=1.19 (95%CI: 1.18-1.20) 
 
OR of Individual comorbidities for each 






















CCI as prognostic factor; 
Summary scores as a continuous 
variable; 
Summary scores quartile to 4 
categories (cut-off values varied, no 
further information found). 
Cox proportional 
hazard regression 
No results from unadjusted models. 
 
6-month mortality (not complete):  
Results from adjusted models: 
HR=1.15 (95%CI: 1.06-1.26) 
4 vs 1: HR=6.19 (95%CI: 2.95-12.95) 
 
6-month readmissions(not complete):  
Results from adjusted models: 
HR=1.15 (95%CI: 1.06-1.26) 










The original CCI  
(19 conditions) 
CCI as prognostic factor; 
Summary scores as a continuous 
variable;  




Results from unadjusted models: 
HR=1.40 (95%CI: 1.31-1.51) 
Results from adjusted models: 
HR=1.14 (95%CI: 1.03-1.25) 
 
6-month mortality: 
Results from unadjusted models: 
HR=1.43 (95%CI: 1.34-1.52) 
Results from adjusted models: 
HR=1.19 (95%CI: 1.10-1.29) 
 
2-year mortality: 
Results from unadjusted models: 
HR=1.45 (95%CI: 1.38-1.52) 
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HR=1.25 (95%CI: 1.18-1.33) 
 
HR of Individual comorbidities for each 
outcome in Table 2 and 3 in the paper. 
CCI: Charlson comorbidity index; HR: hazard ratio; CI: confidence interval; SAMI: Soroka acute myocardial infarction; OR: odd ratio; SCM: simplified comorbidity measure; 
SCI: simple comorbidity index; CS: chronic comorbidity score; HF: heat failure; MACE: major acute cardiovascular events; NA: not available; ECS: Elixhauser comorbidity 
score; MACCE: major acute cardiovascular and cerebrovascular events.  
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